Design, synthesis, and in vitro antiproliferative activity of novel 4-amino-6-phenoxyquinoline and 4,6-diphenoxyquinoline
Open Access
- 30 April 2026
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (25) , 22647-22658
Abstract
This study aimed to synthesize and biologically evaluate novel 4-amino-6-phenoxyquinoline and 4,6-diphenoxyquinoline derivatives with potential anticancer activity. The newly synthesized compounds were screened for cytotoxicity against a panel of seven human cancer and normal cell lines using the MTT assay to determine IC50 values, with sorafenib included as a reference drug. Among the tested molecules, compounds 7a and 7b demonstrated the most potent and selective reduction in cell viability, particularly in A549 lung carcinoma, PANC-1 pancreatic cancer, and MCF-7 breast cancer cells, and were therefore selected for further mechanistic investigations. Flow cytometry-based Annexin V/PI analysis revealed significant induction of apoptosis and necrosis following treatment, with pronounced effects observed in A549 and PANC-1 cells exposed to compound 7a and sorafenib. Acridine orange staining further confirmed a marked increase in autophagic activity across all examined cancer cell lines, indicating the activation of additional cell death pathways. Cell cycle analysis demonstrated compound- and cell-type-dependent effects, including S-phase arrest in A549 and PANC-1 cells and G1-phase arrest in MCF-7 cells. Collectively, these findings indicate that 4-amino-6-phenoxyquinoline derivatives exert anticancer effects through coordinated induction of apoptosis, autophagy, and cell cycle arrest, supporting their potential as promising candidates for further anticancer drug development.Keywords
Funding Information
- University of Petra
This publication has 15 references indexed in Scilit:
- Molecular target interactions of quinoline derivatives as anticancer agents: A reviewChemical Biology & Drug Design, 2022
- RETRACTED: Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin ActivityPharmaceuticals, 2020
- Design, synthesis and biological evaluation of 6‐substituted quinolines derived from cabozantinib as c‐Met inhibitorsArchiv der Pharmazie, 2019
- Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based DesignJournal of Medicinal Chemistry, 2017
- Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agentsEuropean Journal of Medicinal Chemistry, 2017
- Design, Synthesis, and Cytotoxic Evaluation of Certain 7‐Chloro‐4‐(piperazin‐1‐yl)quinoline Derivatives as VEGFR‐II InhibitorsArchiv der Pharmazie, 2017
- Controlled Fluoroalkylation Reactions by Visible-Light Photoredox CatalysisAccounts of Chemical Research, 2016
- Derivatives of 6-cinnamamido-quinoline-4-carboxamide impair lysosome function and induce apoptosisOncotarget, 2016
- Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline DerivativesMolecules, 2015
- Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitorBioorganic & Medicinal Chemistry Letters, 2014